



II INTERNATIONAL THORACIC CANCER DEBATES

FEBRUARY 1ST, 2ND & 3RD 2024, CANARY ISLANDS





SCIENTIFIC COORDINATORS ORGANIZED BY

Dr. Delvys Rodríguez Abreu.

Hospital Universitario Insular, Las Palmas de Gran Canaria. Spain

Dr. Rosario García Campelo.

Complejo Hospitalario Universitario de A Coruña, La Coruña. Spain

Dr. Luis Paz-Ares Rodríguez.

Hospital Universitario 12 de Octubre, Madrid. Spain

THURSDAY 1ST FEBRUARY

19:00 - 19:45

SIMPOSIUM

19:00 - 19:15

FIRST-LINE TREATMENTS

Dr. Ben Solomon. Peter MacCallum Cancer Centre in Melbourne. Australia

19:15 - 19:45

Lecture: Lung Cancer screening. Only for smoker and exsmoker?

Dr. Ben Solomon. Peter MacCallum Cancer Centre in Melbourne. Australia

Dr. Javier de Castro. Hospital de La Paz, Madrid. Spain

Dr. Rodríguez. Hospital Universitario Insular de Gran Canaria, Canary Islands. Spain



FRYDAY 2ND FEBRUARY

09:00 – 09:15

Welcome and Institutional opening

Dr. Delvys Rodríguez Abreu. Hospital Universitario Insular de Gran Canaria, Canary Islands, Spain

Dr. Rosario García Campelo. Complejo Hospitalario Universitario de A Coruña, Spain

Dr. Luis Paz-Ares Rodríguez. Hospital Universitario 12 de Octubre, Madrid, Spain

09:15 – 09:35

Lecture: Lung Cancer screening. Only for smoker and exsmoker?

Ugo Pastorino. Istituto Nazionale dei Tumori, Milan, Italy

09:35 – 09:45



Debate: Pilar Garrido and Juan Carlos Trujillo-Reyes

09:45 – 12:05

SESSION I – EARLY AND LOCALLY ADVANCED NSCLC

CHAIRS:

Antonio Araujo. Hospital Universitario de Oporto, Portugal

Enriqueta Felip. Hospital Universitario Vall D'Hebron de Barcelona, Spain

09:45 – 10:00

Stage I/II Neoadjuvant IO or Adjuvant IO

Patrick Forde. Johns Hopkins Kimmel Cancer Center, Washington, USA

10:00 – 10:15

Stage III Neoadjuvant for all? New options in non pCR

Mariano Provencio. Hospital Universitario Puerta del Hierro Majadahonda, Madrid

10:15 – 10:30

Stage III Chemoradiotherapy and IO consolidation for all? New options

Raffaele Califano. The Christie NHS Foundation Trust, Manchester, UK

10:30 – 10:45

Surgery challenge after Neoadjuvant in NSCLC?

Isabelle Schmitt-Opitz. University Hospital Zurich, Switzerland

10:45 – 10:55



Panel Discussion. Luis Paz-Ares and Anna Estival

10:55 – 11:10

NSCLC with driver mutation. Is neoadjuvant the best approach?

Jon Zugazagoitia MD PhD. Hospital Universitario 12 de Octubre, Madrid, Spain

11:10 – 11:25

NSCLC with driver mutation. Is adjuvant the best approach?

Ben Solomon. Peter MacCallum Cancer Centre in Melbourne, Australia

11:25 – 11:40

Biomarkers in early stage NSCLC and the role of pathology

Fernando Lopez-Rios. Hospital Universitario 12 de Octubre, Madrid, Spain

11:40 – 12:05



Panel Discussion. Rosario Garcia and David Aguiar

12:05 – 12:35



COFFEE BREAK



12:35 – 13:50

SESSION 2 – METASTASTIC NSCLC WITHOUT DRIVER MUTATIONS I

CHAIRS:

Bartomeu Massuti. Hospital Universitario Dr. Balmis, Alicante. Spain

Jair Bar. Institute of Oncology, Sheba Medical Center. Israel

12:35 – 12:50

In PDL1>50%. The same question after 5ys. Who will beat the Troya Horse?

Martin Reck. Lung Clinic Grosshansdorf. Germany

12:50 – 13:05

Must be the combo of anti PD1/L1 plus anti CTLA4 the standard in PDL1 neg?

Solange Peters. Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne. Switzerland

13:05 – 13:20

Will be the CT combo with anti PD1/L1 plus anti TIGIT or Lag3 the new standard in 1L for all comers?

Dr. Delvys Rodríguez Abreu. Hospital Universitario Insular, Las Palmas de Gran Canaria

13:20 – 13:35

Will be the anti PD1/L1 plus ADCs the new standard in 1L?

Marina Garassino. The University of Chicago. USA

13:35 – 13:50



Panel Discussion. Virginia Calvo and Margarita Majem

13:50 – 15:05



LUNCH BREAK

15:05 – 18:00

SESSION 3 – METASTASTIC NSCLC WITHOUT DRIVER MUTATIONS II

CHAIRS:

Dolores Isla. Hospital Universitario Insular, Las Palmas de Gran Canaria. Spain

Javier De Castro. Hospital La Paz, Madrid. Spain

15:05 – 15:15

What is second line nowadays in wtNSCLC and how many patients receive it?

Joachim Aerts. Erasmus MC in Rotterdam. The Netherlands

15:15 – 15:30

Mechanisms of resistance to immunotherapies but this time even in early stage.

Jarushka Naidoo. Beaumont RCSI Cancer Centre. Dublin

15:30 – 15:45

NewIO combinations after IO failure

Dr. Rosario García Campelo. Complejo Hospitalario Universitario de A Coruña. Spain

15:45 – 15:55



Panel Discussion. Delvys Rodríguez Abreu and Stephen Liu

15:55 – 16:10

Antibody drug conjugates and Bispecific antibodies after IO failure

Federico Cappuzzo. Istituto Nazionale Tumori Regina Elena, Roma. Italy

16:10 – 16:25

Still a place for targeting TAM receptors after IO failure

Jair Bar. Institute of Oncology, Sheba Medical Center. Israel

16:25 – 16:40

T cell therapy in NSCLC after IO failure

Marco Donia. National Center for Cancer Immune Therapy. Denmark

16:40 – 16:50



Panel Discussion. Sergio Vazquez and Hossein Borghaei



16:50 - 18:15

SESSION 4 - SCLC AND OTHERS ISSUES

CHAIRS:

Manuel Cobo. Hospital Carlos Haya de Málaga. Spain

Ignacio Gil Bazo. Instituto Valenciano de Oncología. Spain

16:50 - 17:05

How to improve 1L treatment in mSCLC

Stephen Liu. Lombardi Cancer Center Georgetown University, Washington. USA

17:05 - 17:20

Seconds line SCLC

Hossein Borghaei. Fox Chase Cancer Center, Philadelphia. USA

17:20 - 17:35

Mesothelioma. Is immunotherapy finally changing the paradigm?

Jose Manuel Trigo. Hospital Marbella. Spain

17:35 - 17:45



Panel Discussion. Elisa González and Rolf Stahel

17:45 - 18:00

Brain metastasis: In mNSCLC, do we need radiotherapy on front?

Ernest Nadal. IICO, Hospital Duran i Reynald, Hospitalet de Llobregat, Barcelona. Spain

18:00 - 18:15

Thymic Carcinoma. Finally Something new?

Claudia Proto. Instituto Nazionale dei Tumori, Milan. Italy

18:15 - 18:25



Panel Discussion. Martín Lázaro and Rolf Stahel

18:25 - 18:40



CLOSING REMARKS

20:30



DINNER



SATURDAY 3RD FEBRUARY

09:00 - 12:30 **SESSION 5 - TARGET THERAPIES**

CHAIRS:

Margarita Majem. Hospital de la Santa Creu i Sant Pau, Barcelona. Spain
Rolf Stahel. ETOP. Switzerland

09:05 - 09:20

EGFRm NSCLC. Chemo-TKI the new SoC for everybody?

Dr. Luis Paz-Ares. Hospital Universitario 12 de Octubre, Madrid. Spain

09:20 - 09:35

EGFRm NSCLC. Which one is the best options in 2L?

Julia Rotow. Dana-Farber Cancer Institute. USA

09:35 - 09:50

Exon 20 mutations/insertions. Different disease and different treatment?

Ross Soo. Medical Doctor at National University Hospital. Singapore

09:50 - 10:00



Discussion and Q&A. Alfredo Addeo and Ernest Nadal

10:00 - 10:15

BRAF mutant NSCLC. First TKI or CT/IO

Ignacio Gil Bazo. Instituto Valenciano de Oncología, Valencia. Spain

10:15 - 10:30

MET exon 14 mutated NSCLC. Small group and many different options.

Enriqueta Felip. Hospital Universitario Vall D'Hebron de Barcelona. Spain

10:30 - 10:45

HER2 deregulated NSCLC. How do we should treat those patients?

Antonio Calles. Hospital General Universitario Gregorio Marañón, Madrid. Spain

10:45 - 11:00

RET Fusion Positive NSCLC. Changing the standard of care

Pilar Garrido. Hospital Universitario Ramón y Cajal, Madrid. Spain

11:00 - 11:10



Discussion and Q&A

11:10 - 11:25

KRAS G12C. Combination therapy or monotherapy?

Alfredo Addeo. University Hospital of Geneva. Switzerland

11:25 - 11:40

Others KRAS mutations and new drugs

Santiago Ponce. Institut Gustave Roussy, Paris. France

11:40 - 11:55

mRAS-mediated Adaptive Resistance in KRAS-mutant G12C NSCLC

Rafael Rosell. Hospital Universitari Quirón Dexeus, Barcelona. Spain

11:55 - 12:10

ALK and ROS1 positive NSCLC. Best first-line therapy?

Lorenza Landi. Istituto Nazionale Tumori Regina Elena, Rome. Italy

12:10 - 12:20



Panel Discussion. Javier De Castro and Dolores Isla

12:20 - 12:35

Integration of Biomarkers with Artificial Intelligence

Arsela Prelaj. Istituto Nazionale dei Tumori, Milan. Italy

12:35 - 12:50

Liquid biopsy. Predictive, prognostic or only for follow u.

Christian Rolfo.

12:10 - 12:20



Panel Discussion. Javier De Castro and Dolores Isla

12:50 - 13:05



CLOSING REMARKS. Delvys Rodríguez, Rosario García and Luis Paz-Ares

PLATINIUM

SILVER

BRONZE

COLLABORATORS

WITH THE SCIENTIFIC ENDORSEMENT OF

ORGANIZED BY



FCCCP

**FUNDACIÓN CANARIA
DE CÁNCER DE PULMÓN**